Treatment of central nervous system metastases: Parenchymal, epidural, and leptomeningeal

Current Opinion in Oncology

Volumn 18, Issue 6, 2006, Pages 637-643

  Taillibert, Sophie ^a   Hildebrand, Jerzy ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Brain metastases; Intrathecal chemotherapy; Leptomeningeal metastases; Spinal epidural metastases; Stereotactic radiosurgery

Indexed keywords

ALPHA INTERFERON; ANALGESIC AGENT; ANASTROZOLE; ANGIOSTATIN; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CYTARABINE; DIAZIQUONE; FOLINIC ACID; GEFITINIB; GEMCITABINE; INTERLEUKIN 2; INTERLEUKIN 8; IODINE 131; LETROZOLE; MAFOSFAMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; PENTETATE INDIUM IN 111; RITUXIMAB; SEMAXANIB; TAMOXIFEN; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; TRASTUZUMAB;

ALGORITHM; ARACHNOIDITIS; BONE MARROW SUPPRESSION; BRAIN METASTASIS; BRAIN RADIATION; BRAIN VENTRICLE PERITONEUM SHUNT; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER SURGERY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; FATIGUE; GAMMA KNIFE RADIOSURGERY; HUMAN; HYDROCEPHALUS; LAMINECTOMY; LEPTOMENINX; LUNG SMALL CELL CANCER; MENINGEAL METASTASIS; META ANALYSIS; MUCOSA INFLAMMATION; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEIZURE; SPINAL CORD METASTASIS; STEREOTAXIC SURGERY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; EPIDURAL NEOPLASMS; HUMANS; MENINGEAL NEOPLASMS; RADIOTHERAPY;

EID: 33748886663     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000245323.19411.d7     Document Type: Review

References (61)

1. Slimane K, Andre F, Delaloge S, et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 2004; 15:1640-1644.
2. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97:2972-2977.
3. Lai R, Dang CT, Malkin MG, Aubrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2005; 103:1314-1315. This study, which retrospectively compared 264 patients without and 79 patients with trastuzumab therapy, does not support the association.
4. Diener-West M, Dobbins TW, Philips TL, Nelson DT. Identification of an optimal sub-group for treatment evaluation of patients with brain metastases using RTOG study 7916. Int J Radiat Oncol Biol Phys 1989; 16:669-678.
5. Cao KJ, Huang HY, Tu MC, Pan GY. Long-term results of prophylactic cranial irradiation for limited-stage small-cell lung cancer in complete remission. Chin Med J 2005; 118:1258-1262. A randomized study including 51 patients. The incidence of brain metastases was 3.8% after prophylactic WBRT versus 32% in the control group (P = 0.02); the survival increase did not reach the level of statistical significance (P = 0.13).
6. Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999; 341:476-484.
7. Fuentes S, Delsanti C, Metellus P, et al. Brainstem metastases: management using gamma knife radiosurgery. Neurosurgery 2006; 58:37-42. Twenty-eight patients with brain metastases originating mainly from lung carcinoma (n = 13), and melanoma (n = 4), located either in the pons (n = 17), the midbrain (n = 9), or the medulla (n = 2), were treated with radiosurgery. Only six patients underwent WBRT. Local control was achieved in 92% of the patients and death was related to tumour progression in only two patients. The procedure is considered safe by the authors.
8. Noel G, Bollet MA, Noel S, et al. Linac stereotactic radiosurgery: an effective and safe treatment for elderly patients with brain metastases. Int J Radiat Oncol Biol Phys 2005; 63:1555-1561. The study evaluated radiosurgery in 117 patients aged 65 years or older with brain metastases of miscellaneous origin. Thirty-eight patients had WBRT. The local control rate was 98% at 6 months and 91% at 24 months. Seven patients developed radionecrosis.
9. Jawahar A, Matthew RE, Minagar A, et al. Gamma knife surgery in the management of brain metastases from lung carcinoma: a retrospective analysis of survival, local tumor control, and freedom from new brain metastasis. J Neurosurg 2004; 100:842-847.
10. Mindermann T. Tumor recurrence and survival following gamma knife surgery for brain metastases. J Neurosurg 2005; 102:287-288. The study included 101 patients with various primaries. The rate of local control declined during follow-up.
11. Sheehan J, Kondziolka D, Flickinger J, Lunsford LD. Radiosurgery for patients with recurrent small cell lung carcinoma metastatic to the brain: outcomes and prognostic factors. J Neurosurg 2005; 102:247-254. The study reviews 27 patients with 47 brain metastases. Postradiosurgical imaging showed that 62% of the lesions decreased, 19% remained stable, and 19% eventually increased in size. Postradiosurgery MRI or CT scans were performed in only 14 patients and 21 brain metastases, however.
12. Goyal S, Prasad D, Harrell F Jr, et al. Gamma knife for treatment of intracranial metastases from breast cancer. J Neurosurg 2005; 103:218-223. The study reviewed 43 women with 84 brain metastases. Neuroimaging was performed in 35 patients. The rate of local control declined during follow-up.
13. Deinsberger R, Tidstrand J. Linac radiosurgery as single treatment in cerebral metastases. J Neurooncol 2006; 76:77-83. A total of 110 patients with 161 brain metastases originating from miscellaneous cancers were treated with radiosurgery; 35 patients had upfront WBRT. The median delay between WBRT and radiosurgery was 5 months. Local tumour control was achieved in 89.4% of the patients.
14. Chang EL, Selec U, Hassenbusch SJ 3rd, et al. Outcome variation among radioresistant brain metastases treated with stereotactic radiosurgery. Neurosurgery 2005; 56:936-945. The study reports on 103 patients with melanoma, 77 with renal cell carcinoma, and nine with sarcoma. The rate of local control was higher for renal metastases than in melanoma and higher for melanoma than sarcoma brain metastases. The rate of local control declined during follow-up.
15. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to brain. N Engl J Med 1990; 322:494-500.
16. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of a single brain metastasis: radiotherapy alone or combination with neurosurgery. Ann Neurol 1993; 33:583-590.
17. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with single brain metastasis. Cancer 1996; 78:1470-1476.
18. Paec SH, Audu PB, Sperling MR, et al. Reevaluation of surgery for treatment of brain metastases: review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques. Neurosurgery 2005; 56:1021-1034. In this retrospective analysis, one brain metastasis was resected in 191 patients with single brain metastases and two or more brain metastases were resected in 17 patients. Reversal or stabilization of neurologic deficit and survival advantage were observed mainly in patients with favourable prognostic factors (recurrent partitioning analysis class I).
19. Daniels M, Wright GM. Complete resection of nonsmall-cell cancer and oligo-metastatic brain disease. Aust N Z J Surg 2005; 75:963-966. Complete resection of lung was achieved in 12 of 15 patients with synchronous or metasynchronous brain metastases; 60% of the patients were alive at 5 years.
20. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363:1665-1672.
21. Varlotto JM, Flickinger JC, Niranjan A, et al. The impact of whole brain radiation therapy on the long-term control and mortality of patients surviving more than one year after gamma knife radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 2005; 62:1125-1132. This retrospective analysis considers 110 patients with brain metastases of various origins 1 year or longer after radiosurgery: 70 patients were treated with radiosurgery plus WBRT and 40 with radiosurgery alone. Adding WBRT to radiosurgery improved local control and decreased intracranial relapse in patients with brain metastases of 2 cc or greater, peripheral dose 16 Gy or more, single metastases, nonradioresistant tumours, and lung cancer.
22. Hildebrand J, Brada M. Therapy of the main neurological malignant diseases. In: Differential diagnosis in neuro-oncology. Oxford, UK: Oxford University Press; 2001. pp. 223-287.
23. Kim DY, Lee KW, Yun T, et al. Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from nonsmall cell lung cancer. Oncol Rep 2005; 14:207-211. In this nonrandomized study, 31 of 63 consecutive patients received platinum-based chemotherapy. The median survival was significantly prolonged in the chemotherapy arm (58.1 versus 19.0 weeks, P < 0.001).
24. Namba Y, Kijima T, Tokoya S, et al. Gefitinib in patients with brain metastases from nonsmall-cell cancer: review of 15 clinical cases. Clin Lung Cancer 2004; 6:123-128.
25. Poon AN, Ho SS, Yeo W, Mok TS. Brain metastasis responding to gefitinib alone. Oncology 2004; 67:174-178.
26. Chamberlain MC, Kormanik PA. Epidural spinal cord compression: a single institution's retrospective experience. Neuro-oncology 1999; 1:120-123.
27. Graus F, Krol K, Foley K. Early diagnosis of spinal metastasis: correlation with clinical and radiological findings. Proc Am Soc Clin Oncol 1985; 4:269.
28. Mester U, Lerman H, Blank A, et al. Malignant involvement of the spine: assessment by 18F-FDG PET/CT. J Nucl Med 2004; 45:279-284.
29. van der Sande JJ, Kröger R, Boogert W. Multiple spinal epidural metastases: an unexpected frequent finding. J Neurol Neurosurg Psychiatry 1990; 53:1001-1003.
30. Rades D, Fehlauer F, Hartmann A, et al. Reducing the overall treatment time for radiotherapy of metastatic spinal cord compression (MSCC): 3-year results of a prospective observational multicenter study. J Neurooncol 2004; 70:77-82.
31. Findley GFG. Adverse effects of management of malignant spinal cord compression. J Neurol Neurosurg Psychiatry 1984; 47:653-658.
32. Gilbert RW, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol 1978; 3:40-51.
33. Young RF, Post EM, King GA. Treatment of spinal epidural metastases: randomized prospective comparison of laminectomy and radiotherapy. J Neurosurg 1980; 53:741-748.
34. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal compression caused by metastatic cancer: a randomized trial. Lancet 2005; 366:643-648. The study shows a significant benefit of surgery on the ability to walk (the primary endpoint, P = 0.001), the preservation of the ability to walk (P = 0.003), and the decreased need for corticosteroids and opioid analgesics. The patients were stratified according to institution, tumour type, ambulatory status, and spine stability. It is important to keep in mind that patients were included on the basis of MRI evidence of spinal cord displacement on the cervical and dorsal (not lumbar) level and that patients with multiple spinal compressions and radiosensitive tumours were excluded from the study.
35. Mason WP, Yeh SD, DeAngelis LM. 11 Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 1998; 50:438-444.
36. Glantz MJ, Hall WA, Cole BF, et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995; 75:2919-2931.
37. Sandberg DI, Bilsky MH, Souweidane MM, et al. Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 2000; 47:49-54.
38. DeAngelis LM. Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 1998; 38:245-252.
39. Chamberlain MC. Neoplastic meningitis. J Clin Oncol 2005; 23:3605-3613. An update of the current management of LMM and of the remaining issues in this disease.
40. Chowdhary S, Chamberlain MC. Leptomeningeal metastases: current concepts and management guidelines. J Natl Compr Canc Netw 2005; 3:693-703. An update of the current management of LMM and of the remaining issues in this disease.
41. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999; 5:3394-3402.
42. Shapiro WR, Schmid M, Glantz M, et al. A randomized phase III/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis. Proc Am Soc Clin Oncol 2006; 24(18S):1528. One of the few randomized trials in LMM, confirming the efficacy of cytarabine in LMM secondary to solid tumours and confirming that the agent will lead to an easier schedule of drug administration and an increase in patients' quality of life.
43. Rogers LR, Chamberlain MC, Glantz M. Evidence-based review of intrathecal chemotherapy in outcome of patients with leptomeningeal metastasis. Proc Am Soc Clin Oncol 2006; 24(18S):1529. An interesting evidence-based review of the five prospective, randomized, controlled trials in which intrathecal chemotherapy was used to treat LMM. It concludes that all studies provided only class III evidence. Increases in quality of life, survival, and time to progression in responders suggest that a subset of the treated population may benefit from intrathecal chemotherapy.
44. Siegal T. Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy? J Neurooncol 1998; 38:151-157.
45. Ozdogan M, Samur M, Bozcuk HS, et al. Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection. Jpn J Clin Oncol 2003; 33:229-231.
46. Boogerd W, Dorresteijn LD, van Der Sande JJ, et al. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 2000; 55:117-119.
47. Reijneveld JC, Taphoorn MJ, Kerckhaert OA, et al. Angiostatin prolongs the survival of mice with leptomeningeal metastases. Eur J Clin Invest 2003; 33:76-81.
48. Robins HI, Liu G, Hayes L, Mehta M. Trastuzumab for breast cancer-related carcinomatous meningitis. Clin Breast Cancer 2002; 2:316.
49. Renbarger J, Aleksic A, McGuffey L, et al. Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates. Cancer Chemother Pharmacol 2004; 53:39-42.
50. Blaney SM, Balis FM, Berg S, et al. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol 2005; 23:1555-1563.
51. Sirachainan N, Visudtibhan A, Tuntiyatorn L, et al. Favorable response of intraommaya topotecan for leptomeningeal metastasis of neuroblastoma after intravenous route failure. Pediatr Blood Cancer 2006, Mar 29. [Epub ahead of print]
52. Stemmler HJ, Schmitt M, Harbeck N, et al. Application of intrathecal trastuzumab (Herceptin™) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 2006; 15:1373-1377. Although this is only a case report, it integrates a validated and targeted therapy in the treatment of LMM secondary to c-erb B2-positive breast cancer. These data need to be confirmed in larger studies.
53. Schulz H, Pels H, Schmidt-Wolf I, et al. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 2004; 89:753-754.
54. Choong NW, Dietrich S, Seiwert TY, et al. Gefitinib response of erlotinib-refractory lung cancer involving meninges: role of EGFR mutation. Nat Clin Pract Oncol 2006; 3:50-75. Although this is only a case report, it integrates the newly available targeted therapies in the treatment of LMM. These data need to be confirmed in trials.
55. Reijneveld JC, Brandsma D, Boogerd W, et al. CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology 2005; 65:1120-1122. Integrating LMM in the new era of angiogenesis and consequently in the future development of antiangiogenesis-targeted therapies makes this study very original and promising.
56. Brandsma D, Taphoorn MJB, de Jager W, et al. Interleukin-8 CSF levels predict survival in patients with leptomeningeal metastases. Neurology 2006; 66:243-246. This study introduced a potential new prognostic factor in a domain in which the treatment decision relies on the prognosis.
57. Siomin VE, Vogelbaum MA, Kanner AA, et al. Posterior fossa metastases: risk of leptomeningeal disease when treated with stereotactic radiosurgery compared to surgery. J Neurooncol 2004; 67:115-121.
58. Evans AJ, James JJ, Cornford EJ, et al. Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol (R Coll Radiol) 2004; 16:345-349.
59. Gonzalez-Angulo AM, Cristofanilli M, Strom EA, et al. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer 2004; 101:1760-1766.
60. Komori T, Delbeke D. Leptomeningeal carcinomatosis and intramedullary spinal cord metastases from lung cancer: detection with FDG positron emission tomography. Clin Nucl Med 2001; 26:905-907.
61. Padma MV, Jacobs M, Kraus G, et al. 11C-methionine PET imaging of leptomeningeal metastases from primary breast cancer: a case report. J Neurooncol 2001; 55:39-44.